Monday, February 27, 2023
The new bad boys of healthcare are pharmacy benefit managers (PBMs). The U.S. House and Senate are targeting PBM practices, such as drug manufacturers’ rebates which allegedly hike drug prices. The FTC is preparing a report on PBMs’ impact on drug access and affordability.
The list of allegations leveled against intermediaries like PBMs is lengthy: e.g., anticompetitive behavior, collusion with manufacturers, exclusive contracts, reduced patient access to needed medicine, conflicts of interest, excessive fees, kickbacks, secret rebates, lack of transparency, and higher consumer costs. By contrast, the supporting evidence is scant...
Read More: The Hill
ความคิดเห็น